SUMMARY

OUR STRATEGY

Our mission is to become a global leader in the discovery, development and commercialization
of innovative therapies. In the near term, we are focused on pursuing the following significant
opportunities:

•

•

•

•

•

Globally develop and commercialize zanubrutinib, a potentially best-in-class BTK
inhibitor;

Develop and commercialize our investigational checkpoint
rapidly and favorably evolving China market;

inhibitor,

tislelizumab,

in a

Build a leadership position by further expanding our capabilities;

Take advantage of significant regulatory reforms in China to accelerate global drug
development; and

Expand
pharmaceutical companies to complement our internal research.

portfolio

product

pipeline

through

our

and

collaborations with

other

OUR BUSINESS

Our Pipeline and Commercial Products

The following table summarizes the status of our pipeline and commercial products:

Program (Target)

Commercial 

Rights

Dose Esc

Dose Exp

Pivotal

Phase 1a

Phase 1b Phase 2* Phase 2**

Phase 3

Lead Indications

zanubrutinib  (BGB-3111, BTK)

Worldwide

zanubrutinib + GAZYVA® (BTK + CD20)

ediwdlroW

tislelizumab  (BGB-A317, PD-1)

Worldwide for 

heme 

malignancy, 
Asia ex-Japan 
for solid tumors¹

tislelizumab + pamiparib 

(PD-1 + PARP)

ediwdlroW

tislelizumab + zanubrutinib 

(PD-1 + BTK)

ediwdlroW

pamiparib  (BGB-290, PARP)

Worldwide²

pamiparib + TMZ (PARP + Chemo)

²ediwdlroW

pamiparib + RT/TMZ (PARP + RT/Chemo)

²ediwdlroW

lifirafenib  (BGB-283, RAF Dimer)

Worldwide²

BGB-A333 +/- tislelizumab  (PD-L1 +/- PD-1)

ediwdlroW

BGB-A425  (TIM-3)

REVLIMID ® (IMiD)***

ABRAXANE ® (Albumin-bound paclitaxel)

VIDAZA® (hypomethylating agent)

CC-122  (CELMoD)

sitravatinib  (multi-kinase inhibitor)

ediwdlroW

Planned

China

anihC

anihC

anihC

Asia ex-Japan, 

AU, NZ3

Planned

Planned

Marketed

Marketed

Marketed

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

•

WM, 1L CLL/SLL

R/R MCL, R/R CLL/SLL, WM (pivotal Ph2)

)2hP latovip( LF R/R

2L NSCLC, 1L HCC, 2L ESCC

1L NSCLC

R/R cHL, 2L+ UC (pivotal Ph2)

2L/3L HCC (pivotal Ph2)

R/R NK/T-cell lymphomas

sromutdiloS

seicnangilam llec-B

1L plat-sensitive GC maintenance

2L plat-sensitive OC maintenance

3L gBRCA+ OC (pivotal Ph2)

Solid tumors

sromutdiloS

amotsalboilG

B-Raf- or K-RAS/N-RAS-mutated solid tumors

B-Raf- or K-RAS/N-RAS-mutated solid tumors

sromut diloS

sromut diloS

R/R MM (marketed), NDMM (marketed), R/R NHL 
(Phase 3)

recnac tsaerB

LoMMC,stsalb worram enob %03-02 htiw LMA ,SDM

LHN

NSCLC

*Some indications will not require a non-pivotal Phase 2 clinical trial prior to beginning pivotal Phase 2 or 3 clinical trials. **Confirmatory clinical trials post approval are required for accelerated approvals. ***Revlimid 
approved as a combination therapy with dexamethasone.1 Celgene has the right to develop and commercialize tislelizumab in solid tumors in the United States, European Union, Japan and  the rest-of-world outside of  
Asia.2 Limited collaboration with Merck KGaA.3 Partnership with Mirati Therapeutics, Inc. 

China

Global (ex-
China)

Global (China 
included)

— 4 —

